- Home
- OMER vs STK Comparison
OMER vs STK Comparison
Compare OMER & STK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OMER
- STK
- Stock Information
- Founded
- OMER 1994
- STK 2009
- Country
- OMER United States
- STK United States
- Employees
- OMER N/A
- STK N/A
- Industry
- OMER Biotechnology: Pharmaceutical Preparations
- STK Investment Managers
- Sector
- OMER Health Care
- STK Finance
- Exchange
- OMER Nasdaq
- STK Nasdaq
- Market Cap
- OMER 397.1M
- STK 434.6M
- IPO Year
- OMER 2009
- STK N/A
- Fundamental
- Price
- OMER $3.22
- STK $29.83
- Analyst Decision
- OMER Buy
- STK
- Analyst Count
- OMER 4
- STK 0
- Target Price
- OMER $22.50
- STK N/A
- AVG Volume (30 Days)
- OMER 1.2M
- STK 38.2K
- Earning Date
- OMER 05-15-2025
- STK 01-01-0001
- Dividend Yield
- OMER N/A
- STK 6.60%
- EPS Growth
- OMER N/A
- STK N/A
- EPS
- OMER N/A
- STK N/A
- Revenue
- OMER N/A
- STK N/A
- Revenue This Year
- OMER N/A
- STK N/A
- Revenue Next Year
- OMER $2,447.88
- STK N/A
- P/E Ratio
- OMER N/A
- STK N/A
- Revenue Growth
- OMER N/A
- STK N/A
- 52 Week Low
- OMER $3.00
- STK $24.95
- 52 Week High
- OMER $13.60
- STK $34.31
- Technical
- Relative Strength Index (RSI)
- OMER 23.29
- STK 66.25
- Support Level
- OMER $3.79
- STK $29.47
- Resistance Level
- OMER $6.58
- STK $29.95
- Average True Range (ATR)
- OMER 0.59
- STK 0.45
- MACD
- OMER -0.33
- STK 0.28
- Stochastic Oscillator
- OMER 5.43
- STK 96.06
About OMER Omeros Corporation
Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.
About STK Columbia Seligman Premium Technology Growth Fund Inc
Columbia Seligman Premium Technology Growth Fund Inc is a closed-end management investment company. Its investment objective is to seek growth of capital and current income. The fund invests in various sectors such as consumer discretionary, industrials, information technology and telecommunication services. Columbia Management Investment Advisers, LLC serves as the investment manager to the fund.